These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17460778)

  • 1. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.
    Cengel KA; Voong KR; Chandrasekaran S; Maggiorella L; Brunner TB; Stanbridge E; Kao GD; McKenna WG; Bernhard EJ
    Neoplasia; 2007 Apr; 9(4):341-8. PubMed ID: 17460778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.
    Brunner TB; Cengel KA; Hahn SM; Wu J; Fraker DL; McKenna WG; Bernhard EJ
    Cancer Res; 2005 Sep; 65(18):8433-41. PubMed ID: 16166322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
    Kimple RJ; Vaseva AV; Cox AD; Baerman KM; Calvo BF; Tepper JE; Shields JM; Sartor CI
    Clin Cancer Res; 2010 Feb; 16(3):912-23. PubMed ID: 20103665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
    Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
    Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosensitizing effects of the prenyltransferase inhibitor AZD3409 against RAS mutated cell lines.
    Cengel KA; Deutsch E; Stephens TC; Voong KR; Kao GD; Bernhard EJ
    Cancer Biol Ther; 2006 Sep; 5(9):1206-10. PubMed ID: 16969121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines.
    Bernhard EJ; Stanbridge EJ; Gupta S; Gupta AK; Soto D; Bakanauskas VJ; Cerniglia GJ; Muschel RJ; McKenna WG
    Cancer Res; 2000 Dec; 60(23):6597-600. PubMed ID: 11118040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
    Jin K; Park S; Ewton DZ; Friedman E
    Cancer Res; 2007 Aug; 67(15):7247-55. PubMed ID: 17671193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-κB Axis that induces expression of MMP9 and uPA in human pancreas progenitor cells.
    Bera A; Zhao S; Cao L; Chiao PJ; Freeman JW
    PLoS One; 2013; 8(12):e82282. PubMed ID: 24340014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance.
    Grana TM; Sartor CI; Cox AD
    Cancer Res; 2003 Nov; 63(22):7807-14. PubMed ID: 14633707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells.
    Lee S; Heinrich EL; Lu J; Lee W; Choi AH; Luu C; Chung V; Fakih M; Kim J
    Pancreas; 2016 Feb; 45(2):286-92. PubMed ID: 26262587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity.
    Toulany M; Baumann M; Rodemann HP
    Mol Cancer Res; 2007 Aug; 5(8):863-72. PubMed ID: 17699110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
    Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
    Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells.
    Watanabe M; Nobuta A; Tanaka J; Asaka M
    Int J Cancer; 1996 Jul; 67(2):264-8. PubMed ID: 8760597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.
    Chung EJ; Urick ME; Kurshan N; Shield W; Asano H; Smith PD; Scroggins BS; Burkeen J; Citrin DE
    Int J Oncol; 2013 Jun; 42(6):2028-36. PubMed ID: 23588995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.
    Xu D; Allsop SA; Witherspoon SM; Snider JL; Yeh JJ; Fiordalisi JJ; White CD; Williams D; Cox AD; Baines AT
    Carcinogenesis; 2011 Apr; 32(4):488-95. PubMed ID: 21262926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic K-ras activates p38 to maintain colorectal cancer cell proliferation during MEK inhibition.
    van Houdt WJ; de Bruijn MT; Emmink BL; Raats D; Hoogwater FJ; Borel Rinkes IH; Kranenburg O
    Cell Oncol; 2010 Jan; 32(4):245-57. PubMed ID: 20413844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.